Taiwanese Biotechnology Companies in Parkinson's Disease

Migration, Crosslink

📖

Taiwanese Biotechnology Companies in Parkinson's Disease

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-taiwan-pd-biotech

📖 Wiki Page

company2756 wordssynced 2026-04-02

Overview

flowchart TD companies_taiwan_pd_biotech["Taiwanese Biotechnology Companies in Parkinsons"] style companies_taiwan_pd_biotech fill:#4fc3f7,stroke:#333,color:#000 companies_taiwan_pd__0["Major Taiwanese PD Companies"] companies_taiwan_pd_biotech -->|"includes"| companies_taiwan_pd__0 style companies_taiwan_pd__0 fill:#81c784,stroke:#333,color:#000 companies_taiwan_pd__1["TaiRx Inc"] companies_taiwan_pd_biotech -->|"includes"| companies_taiwan_pd__1 style companies_taiwan_pd__1 fill:#ef5350,stroke:#333,color:#000 companies_taiwan_pd__2["PharmaEssentia Corp"] companies_taiwan_pd_biotech -->|"includes"| companies_taiwan_pd__2 style companies_taiwan_pd__2 fill:#ffd54f,stroke:#333,color:#000 companies_taiwan_pd__3["Hope Biomedical Inc"] companies_taiwan_pd_biotech -->|"includes"| companies_taiwan_pd__3 style companies_taiwan_pd__3 fill:#ce93d8,stroke:#333,color:#000 companies_taiwan_pd__4["TaiGen Biotechnology"] companies_taiwan_pd_biotech -->|"includes"| companies_taiwan_pd__4 style companies_taiwan_pd__4 fill:#4fc3f7,stroke:#333,color:#000 companies_taiwan_pd__5["Taiwan Lipids"] companies_taiwan_pd_biotech -->|"includes"| companies_taiwan_pd__5 style companies_taiwan_pd__5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Taiwan has emerged as a significant hub for biotechnology innovation in the Asia-Pacific region, with a particular focus on developing therapeutics for neurodegenerative diseases, including Parkinson's disease (PD). The island nation's biotechnology sector combines strong academic research capabilities, government support through the Ministry of Economic Affairs and Ministry of Health and Welfare, and an increasing number of biotechnology companies focused on developing novel therapies for neurological disorders["@taiwan2026"].

Taiwanese biotech companies are particularly active in several key areas relevant to Parkinson's disease treatment and research:

Stem Cell Therapy: Taiwan has established itself as a leader in stem cell research and cell therapy development, with multiple companies working on mesenchymal stem cell (MSC) therapies and induced pluripotent stem cell (iPSC) technologies for PD treatment
Small Molecule Drug Development: Taiwanese pharmaceutical companies are developing novel small molecule therapeutics targeting various aspects of PD pathogenesis, including alpha-synuclein aggregation, dopamine receptor modulation, and neuroprotective pathways
Drug Delivery Technologies: Several Taiwanese companies are focused on advanced drug delivery systems, including lipid nanoparticle technology and blood-brain barrier penetration strategies
Biomarker Development: Research institutions and companies in Taiwan are actively working on biomarkers for early PD detection and treatment response monitoring

The combination of academic excellence, government support, and an increasing private sector focus has positioned Taiwan as an important contributor to global Parkinson's disease research and therapy development.

Major Taiwanese PD Companies

TaiRx Inc

TaiRx Inc (泰瑞藥業) is a Taiwanese pharmaceutical company headquartered in Taipei, Taiwan, focused on developing innovative therapeutics for neurodegenerative diseases, including both Alzheimer's disease and Parkinson's disease[@tairx].

Company Overview:

Headquarters: Taipei, Taiwan
Founded: 2015
Focus: CNS drug development, neurodegenerative diseases
Approach: Small molecule therapeutics, CNS drug delivery

Research Programs:

TaiRx's Parkinson's disease program focuses on developing disease-modifying therapies that target the underlying pathophysiology of PD rather than merely providing symptomatic relief. The company's approach includes:

Alpha-Synuclein Modulation: Development of compounds that prevent or reduce the aggregation of alpha-synuclein protein, which is central to PD pathogenesis

Neuroprotective Agents: Small molecules designed to protect dopaminergic neurons from degeneration

Dopamine Receptor Modulators: Novel compounds targeting dopamine receptors with improved safety profiles compared to current therapies

Pipeline Status:

Preclinical programs in alpha-synuclein aggregation inhibitors
Lead optimization ongoing for neuroprotective candidates
Potential IND-enabling studies planned

Strategic Partnerships:
TaiRx has established collaborations with academic institutions in Taiwan, including National Taiwan University and Academia Sinica, for basic research and target validation.

PharmaEssentia Corp

PharmaEssentia Corp (藥華醫藥) is a Taiwanese biopharmaceutical company headquartered in Taipei, with operations focused on developing novel protein therapeutics for hematology, oncology, and central nervous system disorders[@pharmaessentia].

Company Overview:

Headquarters: Taipei, Taiwan
Founded: 2003
Focus: Protein therapeutics, PEGylation technology, CNS disorders
Website: pharmaessentia.com

Technology Platform:

PharmaEssentia's core technology platform is based on PEGylation—the covalent attachment of polyethylene glycol (PEG) to therapeutic proteins to improve their pharmacological properties. This platform has applications in developing long-acting therapeutics for neurological conditions.

Parkinson's Disease Program:

While PharmaEssentia is primarily known for its hematology and oncology programs, the company has expressed interest in expanding into neurological disorders, including Parkinson's disease. The company's PEGylation technology could potentially be applied to:

Long-Acting Dopamine Agonists: PEGylated versions of existing dopamine agonists with extended half-life

Neurotrophic Factors: PEGylated growth factors that support dopaminergic neuron survival

Enzyme Replacement: PEGylated enzymes that could address metabolic aspects of PD

Pipeline Status:

CNS programs in early discovery stages
Technology platform available for partnership
Interest in PD program expansion

Hope Biomedical Inc

Hope Biomedical Inc (再生生物科技) is a Taiwanese biotechnology company specializing in stem cell therapy and regenerative medicine, with a particular focus on cell-based treatments for Parkinson's disease and other neurological conditions[@hopebiomed].

Company Overview:

Headquarters: Taipei, Taiwan
Founded: 2012
Focus: Stem cell therapy, regenerative medicine, mesenchymal stem cells
Approach: MSC therapy for Parkinson's disease

Cell Therapy Platform:

Hope Biomedical has developed a comprehensive cell therapy platform based on mesenchymal stem cells (MSCs), which are derived from various tissue sources including bone marrow, adipose tissue, and umbilical cord.

Mechanism of Action:

MSC-based therapy for Parkinson's disease operates through multiple mechanisms:

Cell Replacement: Potential to differentiate into dopamine-producing neurons

Neuroprotection: Secretion of neurotrophic factors (BDNF, GDNF) that protect existing dopaminergic neurons

Immunomodulation: Reduction of neuroinflammation through anti-inflammatory cytokine secretion

Paracrine Signaling: Enhancement of endogenous repair mechanisms

Clinical Development:

Hope Biomedical's Parkinson's disease program is advancing through clinical development:

Preclinical studies demonstrating safety and efficacy in animal models
IND-enabling studies completed
Planning for Phase 1/2 clinical trials in Taiwan

Advantages of MSC Therapy:

| Advantage | Description |
|----------|-------------|
| Allogeneic Source | Off-the-shelf availability from donors |
| Safety Profile | Established safety in other clinical applications |
| Immunomodulation | Reduced risk of immune rejection |
| Scalability | Potential for large-scale manufacturing |

TaiGen Biotechnology

TaiGen Biotechnology (台灣微脂體) is a Taiwanese pharmaceutical company focused on developing novel small molecule drugs and advanced drug delivery systems for central nervous system disorders and other therapeutic areas[@taigen].

Company Overview:

Headquarters: Taipei, Taiwan
Founded: 2000
Focus: Novel antibiotics, CNS disorders, drug delivery
Approach: Small molecule drug development, lipid-based delivery

CNS Drug Development:

TaiGen's CNS program includes candidates for Parkinson's disease and other neurological disorders:

Dopamine Receptor Modulators: Novel compounds targeting dopamine receptors with improved selectivity and reduced side effects

MAOB Inhibitors: Next-generation monoamine oxidase B inhibitors for symptomatic PD treatment

Neuroprotective Agents: Compounds targeting oxidative stress and mitochondrial dysfunction in PD

Drug Delivery Platform:

TaiGen has developed advanced drug delivery technologies that could benefit PD therapeutics:

Lipid Nanoparticles: Enhanced delivery of CNS drugs across the blood-brain barrier

Sustained Release Formulations: Extended-release formulations for improved patient compliance

Targeted Delivery: Tissue-specific targeting of dopaminergic neurons

Pipeline Status:

Lead candidates in preclinical development
Formulation optimization ongoing
Partnership opportunities for clinical development

Taiwan Lipids

Taiwan Lipids Co., Ltd. (台灣Lipids) is a Taiwanese biotechnology company focused on developing advanced lipid-based drug delivery technologies, with applications in CNS drug delivery for neurodegenerative diseases[@taiwanlipids].

Company Overview:

Headquarters: Taiwan
Focus: CNS drug delivery, lipid nanoparticle technology
Approach: Lipid-based formulations for enhanced brain penetration

Technology Platform:

Taiwan Lipids specializes in lipid-based drug delivery systems, which are particularly relevant for CNS therapeutics due to the blood-brain barrier challenge:

Solid Lipid Nanoparticles: Particles for sustained release and enhanced brain delivery

Lipid Emulsions: Oil-in-water emulsions for improved drug solubility

Liposomes: Phospholipid-based vesicles for targeted delivery

Nanostructured Lipid Carriers: Hybrid systems combining solid and liquid lipids

Applications in Parkinson's Disease:

The company's delivery technology could be applied to:

Enhanced delivery of existing PD drugs (levodopa, dopamine agonists)
Brain delivery of large molecule therapeutics (proteins, oligonucleotides)
Targeted delivery to specific brain regions (substantia nigra, striatum)
Sustained release formulations for improved compliance

Partnerships:
Taiwan Lipids collaborates with pharmaceutical companies and academic institutions to apply its delivery technology to various therapeutic candidates.

New Biotic Inc

New Biotic Inc (新生技) is a Taiwanese biotechnology company developing novel therapeutics for antimicrobial and neurological disorders, including Parkinson's disease[@taiwan2026].

Company Overview:

Headquarters: Taiwan
Focus: Novel therapeutics, neurological diseases
Approach: Small molecule drug discovery

Neurological Program:

New Biotic's neurological focus includes:

PD Drug Development: Novel mechanisms for symptomatic and disease-modifying PD treatment

Neuroinflammation: Targeting neuroinflammatory pathways in PD

Mitochondrial Protection: Compounds protecting mitochondrial function in dopaminergic neurons

Status: Early-stage development with ongoing research programs

Taiwanese PD Research Ecosystem

Academia Sinica

Academia Sinica (中央研究院) is Taiwan's premier research institution and one of Asia's leading scientific organizations. The institute has strong neuroscience research programs highly relevant to Parkinson's disease[@academia].

Relevant Institutes:

Institute of Molecular Biology (IMB)

Research on molecular mechanisms of neurodegeneration
Protein aggregation studies (alpha-synuclein, tau)
Cellular stress response pathways

Institute of Biomedical Sciences

Translational research on neurological diseases
Biomarker discovery for PD
Drug target validation

Institute of Chemistry

Small molecule drug discovery
Medicinal chemistry
Natural product chemistry

Institute of Physiology

Neurophysiology research
Basal ganglia function
Dopamine signaling pathways

Key Research Areas:

Alpha-synuclein aggregation mechanisms
[Mitochondrial dysfunction in PD](/mechanisms/pd-mitochondrial-dysfunction)
Neuroinflammation and glial cell biology
Gene-environment interactions in PD
Biomarker development for early detection

National Taiwan University (NTU)

National Taiwan University (國立臺灣大學) is Taiwan's leading university with extensive neuroscience research capabilities and clinical infrastructure for PD research[@ntu].

Neuroscience Programs:

Department of Neurology - Clinical PD research and trials
College of Medicine - Basic neuroscience research
Center for Parkinson's Disease - Comprehensive care and research

Research Strengths:

Clinical trials infrastructure for PD
Stem cell research programs
Imaging research (MRI, PET)
Genetic studies of Taiwanese PD patients

Clinical Capabilities:

Parkinson's disease specialty clinic
Movement disorders center
Deep brain stimulation program
Clinical trial coordination

National Yang Ming Chiao Tung University (NYCU)

National Yang Ming Chiao Tung University (國立陽明交通大學) is a leading research university with strong programs in biomedical sciences and neurological disorder research[@nymcu].

Research Focus:

Neurological disorder research
Drug discovery programs
Neuroimaging
Biomedical engineering

Key Departments:

Department of Biomedical Engineering
Institute of Brain Science
Department of Pharmacology

Contributions:

Drug screening platforms
Animal models of PD
Mechanism of action studies
Therapeutic candidate evaluation

Taipei Medical University (TMU)

Taipei Medical University (臺北醫學大學) is a leading medical university with strong clinical research capabilities and Parkinson's disease clinical trials infrastructure[@tmu].

Clinical Research:

PD clinical trials
Biomarker research
Clinical outcomes studies
Rehabilitation research

Hospitals:

Taipei Medical University Hospital
Wan Fang Hospital
Shuang Ho Hospital

Programs:

Movement Disorders Center
Neurological rehabilitation
Clinical trial coordination
Patient care excellence

Government Support and Investment

Ministry of Health and Welfare

The Ministry of Health and Welfare (衛生福利部) provides regulatory support and policy framework for biotech development in Taiwan[@doh].

Support Programs:

Regulatory guidance for innovative therapies
Fast-track approval pathways for cell therapies
Orphan drug designation for PD therapies
Reimbursement frameworks for advanced therapies

Regulatory Framework:

Taiwan FDA (TFDA) oversight
Cell therapy regulations
Gene therapy guidelines
Innovative drug expedited pathways

Ministry of Economic Affairs

The Ministry of Economic Affairs (經濟部) drives biotechnology industry development through various programs and incentives[@moea].

Biotech Development Programs:

Biotechnology Innovation and Promotion Program

R&D subsidies for biotech companies
Tax incentives for R&D spending
Seed funding for emerging companies

Industrial Technology Development

Technology development grants
Manufacturing infrastructure support
Export assistance

Biotech Talent Development

Training programs for biotech workforce
International collaboration support
Academic-industry partnerships

National Development Fund

The National Development Fund (國家發展基金) provides investment capital for strategic industries including biotechnology[@ncc].

Investment Focus:

Early-stage biotech companies
Strategic emerging technologies
Companies with high growth potential
Critical therapeutic areas

Investment Criteria:

Innovation and differentiation
Management team quality
Market potential
Strategic alignment with national goals

Taiwan Biotechnology Investment Forum

The Taiwan Biotechnology Investment Forum (台灣生技投資論壇) connects investors with biotech companies and facilitates funding for PD therapeutics development[@biotechforum].

Activities:

Investment conferences
Company presentations
Investor matching
Industry networking

Investment Landscape

Venture Capital and Investment

Key Taiwanese VC and Investment Organizations:

| Organization | Focus | Investment Stage |
|-------------|-------|-----------------|
| Taiwan Biotech VC | Life sciences | Early to growth |
| CTBC Capital | Healthcare | Growth |
| Cathay Capital | Cross-border | Growth |
| WI Harper | Technology/Healthcare | Early to growth |
| CDIB Capital | Healthcare | Multiple stages |

Investment Themes in PD:

Cell Therapy: Significant investment in stem cell companies

Small Molecule: Drug development for novel mechanisms

Drug Delivery: Advanced delivery technologies

Biomarkers: Diagnostic and patient selection tools

Science Parks

Taiwan's science parks provide infrastructure and support for biotechnology companies[@tsp].

Key Parks:

Hsinchu Science Park (新竹科學園區)

Taiwan's "Silicon Valley"
Biotechnology cluster
Research infrastructure
Proximity to academic institutions[@hsinchupark]

Taipei Science Park (臺北科學園區)

CNS and biotech focus
Proximity to clinical sites
Startup support programs

Southern Taiwan Science Park (南部科學園區)

Manufacturing capabilities
Biotech production
Regional development

Park Benefits:

Rent subsidies
Tax incentives
R&D support
Infrastructure access

Clinical Trial Infrastructure

Taiwan's Advantages for PD Clinical Trials

Taiwan offers several advantages for conducting Parkinson's disease clinical trials:

Established Clinical Infrastructure

Major medical centers with PD expertise
Experienced clinical investigators
Established patient registries

Regulatory Efficiency

Streamlined approval processes
TFDA engagement with sponsors
Fast-track options for innovative therapies

Patient Access

Well-organized patient advocacy groups
High treatment compliance
Diverse patient population

Academic Partnerships

Strong university-hospital connections
Basic science integration
Translational research capabilities

Key Clinical Sites

Leading PD Clinical Trial Centers:

National Taiwan University Hospital

Movement Disorders Center
Extensive trial experience
Comprehensive patient database

Taipei Veterans General Hospital

Neurology department
PD research programs
Clinical trials infrastructure

Chang Gung Memorial Hospital

Multiple campuses
Neurology research
Patient access

Taipei Medical University Hospitals

Clinical trial capabilities
Rehabilitation programs
Patient recruitment

Academic Spin-offs and Emerging Companies

University Spin-offs

Research from Taiwanese universities has led to several emerging companies in the PD space:

| Company | University | Technology | Stage |
|---------|------------|------------|-------|
| Hope Biomedical | NTU | MSC therapy | Clinical |
| TaiGen | NYCU | Small molecules | Preclinical |
| Taiwan Lipids | Academia Sinica | Delivery tech | Development |

Emerging Research

Promising Areas:

iPSC Technology: Induced pluripotent stem cell approaches for PD

Gene Therapy: Viral vector-based gene delivery

Immunotherapy: Alpha-synuclein targeting antibodies

Deep Brain Stimulation: Next-generation devices

International Collaboration

Collaborations with Global Institutions

Taiwanese companies and research institutions have established international collaborations:

Academic Collaborations

Joint research with US universities
European research partnerships
Japan-Taiwan collaboration

Industry Partnerships

Licensing agreements with global pharma
Co-development arrangements
Manufacturing partnerships

Clinical Trial Networks

Participation in global trials
Site networks for multi-center studies
Regulatory harmonization

Taiwan-US Collaboration

The US-Taiwan relationship in biotech includes:

FDA regulatory engagement
Academic exchanges
Investment flows
Technology transfer

Challenges and Opportunities

Challenges

Funding Gap: Series A/B funding limitations

Market Size: Limited domestic market

Regulatory Capacity: Need for further TFDA maturation

Talent Pool: Competition for experienced researchers

Opportunities

Asia-Pacific Expansion: Access to regional markets

Cell Therapy Leadership: Established stem cell capabilities

Manufacturing: Strong CDMO infrastructure

Innovation: Novel mechanisms and approaches

Future Directions

Strategic Priorities

Cell Therapy Advancement: Continue leadership in MSC and iPSC technologies

Small Molecule Pipeline: Expand PD drug development programs

Drug Delivery: Leverage delivery technology for brain penetration

Biomarkers: Develop diagnostic and monitoring tools

Growth Drivers

Government support programs
International partnerships
Academic-industry collaboration
Investment in PD research

Emerging Trends

Precision Medicine: Personalized approaches to PD treatment

Combination Therapies: Multiple mechanisms targeting

Digital Health: Monitoring and diagnostic tools

Regenerative Medicine: Cell-based treatments

External Links

[Taiwan Biotechnology Industry Development](https://www.taiwanbio.org.tw/)
[TaiRx Inc](https://www.tairx.com.tw/)
[PharmaEssentia Corp](https://www.pharmaessentia.com/)
[Hope Biomedical Inc](https://www.hopebiomed.com/)
[TaiGen Biotechnology](https://www.taigenbiotech.com/)
[Taiwan Lipids](https://www.taiwanlipids.com/)
[Academia Sinica](https://www.sinica.edu.tw/)
[National Taiwan University](https://www.ntu.edu.tw/)
[National Yang Ming Chiao Tung University](https://www.nycu.edu.tw/)
[Taipei Medical University](https://www.tmu.edu.tw/)
[Taiwan Science Parks](https://www.tsp.org.tw/)
[Ministry of Health and Welfare](https://www.mohw.gov.tw/)
[Ministry of Economic Affairs](https://www.moea.gov.tw/)
[Hsinchu Science Park](https://www.sipa.gov.tw/)
[PubMed - Taiwan Neuroscience](https://pubmed.ncbi.nlm.nih.gov/)

References

[Taiwan Biotechnology Industry Development](https://www.taiwanbio.org.tw/)

[TaiRx Inc Official Website](https://www.tairx.com.tw/)

[PharmaEssentia Corp Official Website](https://www.pharmaessentia.com/)

[Hope Biomedical Inc Official Website](https://www.hopebiomed.com/)

[TaiGen Biotechnology Official Website](https://www.taigenbiotech.com/)

[Taiwan Lipids Official Website](https://www.taiwanlipids.com/)

[Academia Sinica Official Website](https://www.sinica.edu.tw/)

[National Taiwan University](https://www.ntu.edu.tw/)

[National Yang Ming Chiao Tung University](https://www.nycu.edu.tw/)

[Taipei Medical University](https://www.tmu.edu.tw/)

[Taiwan Science Parks](https://www.tsp.org.tw/)

[Taiwan Biotech Council](https://www.biotech.org.tw/)

[Taiwan Ministry of Health and Welfare](https://www.mohw.gov.tw/)

[Taiwan Ministry of Economic Affairs](https://www.moea.gov.tw/)

[National Development Fund Taiwan](https://www.ndf.org.tw/)

[Taiwan Biotechnology Investment Forum](https://www.taiwanbio.com/)

[Taipei Economic and Cultural Office](https://www.taiwanpseos.org/)

[Taipei City Biotechnology Industry Development](https://www.taipeibiodome.com/)

[Hsinchu Science Park](https://www.sipa.gov.tw/)

[PubMed Taiwan Neuroscience](https://pubmed.ncbi.nlm.nih.gov/)

[Taiwan Stem Cell Industry](https://www.taiwanstem.org/)

[Institute of Physiology Academia Sinica](https://www.iom.nctu.edu.tw/)

📖 View canonical wiki page →

Related Entities

companies-taiwan-pd-biotech

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-taiwan-pd-biotech
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e323c4ee8f50
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-taiwan-pd-biotech'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

81

Outgoing

76

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Taiwanese Biotechnology Companies in Parkinson's Disease

Overview

Overview

Major Taiwanese PD Companies

TaiRx Inc

PharmaEssentia Corp

Hope Biomedical Inc

TaiGen Biotechnology

Taiwan Lipids

New Biotic Inc

Taiwanese PD Research Ecosystem

Academia Sinica

National Taiwan University (NTU)

National Yang Ming Chiao Tung University (NYCU)

Taipei Medical University (TMU)

Government Support and Investment

Ministry of Health and Welfare

Ministry of Economic Affairs

National Development Fund

Taiwan Biotechnology Investment Forum

Investment Landscape

Venture Capital and Investment

Science Parks

Clinical Trial Infrastructure

Taiwan's Advantages for PD Clinical Trials

Key Clinical Sites

Academic Spin-offs and Emerging Companies

University Spin-offs

Emerging Research

International Collaboration

Collaborations with Global Institutions

Taiwan-US Collaboration

Challenges and Opportunities

Challenges

Opportunities

Future Directions

Strategic Priorities

Growth Drivers

Emerging Trends

See Also

External Links

References

💬 Discussion